Market environment has remained slow Etteplan released a profit warning due to persistently weak ma...
Redeye provides a short comment on the recently announced directed issue from Scandinavian ChemoTech...
Lower sales but demand for shore power solid Cavotec reported sales of EUR 36m (17% below our estima...
Some customers have postponed their orders due to uncertainties related to the US trade war.
Redeye makes rather small, but positive, changes to our financial forecasts on the back of strong Q2...
Redeye updates its forecast and valuation following Modelon’s Q2 2025 report, which came broadly in ...
Redeye comments on the outcome of AlzeCure’s rights issue, which was significantly oversubscribed at...
India returns to growth and margins expand Medicover delivered another strong quarter, beating adj.
Safello has announced a partnership with Marginalen Bank, positioning itself as the first crypto bro...
Redeye provides an update on NextCell following the company’s Q3 report, which came in largely in li...
Net sales and clean EBIT were below market consensus (LSEG) in Q2.
Redeye updates its estimates and valuation following MedCap’s Q2 2025 report.
Q2 results Medicover reported an adj. EBITDA beat in Q2 (+7%/+7% vs.
Physitrack’s Q2 2025 results came in broadly in line with our expectations.
Redeye shares its initial view on Modelon’s Q2 2025 report.
